Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on immuno-dermatology innovations, has reported the grant of 38,000 restricted stock units to four newly hired employees. The awards were approved by the Compensation Committee of Arcutis' Board of Directors under the company's 2022 Inducement Plan, with a grant date of August 1, 2024.
These stock units are designed as an inducement for new employees joining Arcutis, in compliance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units have a four-year vesting schedule, with 25% vesting on each annual anniversary of the vesting commencement date, contingent on continuous employment with Arcutis.
Arcutis Biotherapeutics (Nasdaq: ARQT), un'azienda biofarmaceutica in fase commerciale focalizzata su innovazioni in immuno-dermatologia, ha annunciato l'assegnazione di 38.000 unità azionarie vincolate a quattro nuovi dipendenti. I premi sono stati approvati dal Comitato per la Retribuzione del Consiglio di Amministrazione di Arcutis nell'ambito del Piano di Induzione 2022 dell'azienda, con una data di assegnazione del 1 agosto 2024.
Queste unità azionarie sono progettate come incentivo per i nuovi dipendenti che si uniscono a Arcutis, in conformità con la Regola di Elenco Nasdaq 5635(c)(4). Le unità azionarie vincolate hanno un programma di maturazione di quattro anni, con il 25% che matura ad ogni anniversario annuale della data di inizio della maturazione, a condizione di un'occupazione continua presso Arcutis.
Arcutis Biotherapeutics (Nasdaq: ARQT), una empresa biofarmacéutica en etapa comercial centrada en innovaciones en inmuno-dermatología, ha informado sobre la concesión de 38,000 unidades de acciones restringidas a cuatro empleados recién contratados. Los premios fueron aprobados por el Comité de Compensación de la Junta Directiva de Arcutis bajo el Plan de Inducción 2022 de la compañía, con una fecha de concesión del 1 de agosto de 2024.
Estas unidades de acción están diseñadas como un incentivo para nuevos empleados que se unen a Arcutis, en cumplimiento con la Regla de Listado Nasdaq 5635(c)(4). Las unidades de acciones restringidas tienen un calendario de adquisición de cuatro años, con un 25% adquiriéndose en cada aniversario anual de la fecha de inicio de la adquisición, sujeto a la continuidad del empleo con Arcutis.
Arcutis Biotherapeutics (Nasdaq: ARQT)는 면역 피부과 혁신에 중점을 둔 상업 단계의 생명공학 회사로, 38,000개의 제한 주식 단위를 신규 채용된 직원 4명에게 수여했다고 보고했습니다. 이 상은 Arcutis 이사회의 보상위원회에 의해 아쿼티스의 2022 유인 계획에 따라 승인되었으며, 부여일은 2024년 8월 1일입니다.
이 주식 단위는 Nasdaq 상장 규칙 5635(c)(4)를 준수하여 Arcutis에 합류하는 신규 직원에 대한 유인으로 설계되었습니다. 제한 주식 단위는 4년의 성숙 일정을 가지고 있으며, 성숙 시작일의 매년 기념일에 25%가 성숙되며, Arcutis와의 지속적인 고용 조건에 따라 이루어집니다.
Arcutis Biotherapeutics (Nasdaq: ARQT), une entreprise biopharmaceutique en phase commerciale axée sur les innovations en immuno-dermatologie, a rapporté avoir accordé 38 000 unités d'actions restreintes à quatre nouveaux employés embauchés. Les récompenses ont été approuvées par le Comité de Rémunération du Conseil d'Administration d'Arcutis dans le cadre du Plan d'Induction 2022 de l'entreprise, avec une date d'octroi du 1er août 2024.
Ces unités d'actions sont conçues comme un incitatif pour les nouveaux employés rejoignant Arcutis, conformément à la Règle de Cotation Nasdaq 5635(c)(4). Les unités d'actions restreintes disposent d'un calendrier d'acquisition de quatre ans, avec 25 % d'acquisition à chaque anniversaire annuel de la date de début de l'acquisition, sous réserve d'un emploi continu chez Arcutis.
Arcutis Biotherapeutics (Nasdaq: ARQT), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf Innovationen in der Immundermatologie konzentriert, hat die Gewährung von 38.000 eingeschränkten Aktieneinheiten an vier neu eingestellte Mitarbeiter bekannt gegeben. Die Zuwendungen wurden vom Vergütungsausschuss des Vorstands von Arcutis im Rahmen des Unternehmensplans zur Induktion 2022 genehmigt, mit einem Gewährungsdatum vom 1. August 2024.
Diese Aktieneinheiten sind als Anreiz für neue Mitarbeiter gedacht, die zu Arcutis kommen, in Übereinstimmung mit der Nasdaq-Listing-Regel 5635(c)(4). Die eingeschränkten Aktieneinheiten unterliegen einem Vesting-Plan von vier Jahren, wobei 25% an jedem jährlichen Jahrestag des Beginns des Vestings fällig werden, abhängig von einer fortlaufenden Beschäftigung bei Arcutis.
- Arcutis is attracting new talent with stock-based compensation
- The company is adhering to Nasdaq listing rules for inducement grants
- None.
WESTLAKE VILLAGE, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 38,000 restricted stock units of Arcutis’ common stock to four newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of August 1, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25 percent vesting on each annual anniversary of the vesting commencement date, subject to the employee being continuously employed by Arcutis as of such vesting dates.
Arcutis is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
Arcutis cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements and you should not place undue reliance on our forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in the clinical development process and regulatory approval process, the timing of regulatory filings, the timing and expenses of commercialization efforts, and our ability to defend our intellectual property. For a further description of the risks and uncertainties applicable to our business, see the “Risk Factors” section of our Form 10-K filed with U.S. Securities and Exchange Commission (SEC) on February 27, 2024, as well as any subsequent filings with the SEC. You should not place undue reliance on any forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Latha Vairavan, Vice President, Finance and Investor Relations
ir@arcutis.com
FAQ
How many restricted stock units did Arcutis Biotherapeutics (ARQT) grant to new employees?
What is the vesting schedule for the restricted stock units granted by Arcutis (ARQT)?
Under which plan were the inducement grants made by Arcutis Biotherapeutics (ARQT)?
What was the grant date for the restricted stock units issued by Arcutis (ARQT)?
